Literature DB >> 18096167

Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome.

Leonardo Gómez Rosso1, María Belén Benítez, María Cecilia Fornari, Vanina Berardi, Santiago Lynch, Laura Schreier, Regina Wikinski, Luis Cuniberti, Fernando Brites.   

Abstract

Metabolic syndrome is considered a hyperinsulinemic and inflammatory state closely associated to endothelial dysfunction causing an increased incidence of ischemic cardiovascular events and high mortality. The main objective of the present study was to determine whether leukocitary and soluble cell adhesion molecules were altered in patients with metabolic syndrome in comparison with control subjects. Cell adhesion molecules, mainly of leukocitary location, have been not previously evaluated in specifically designed cross-sectional studies involving male patients with metabolic syndrome. Moreover, other circulating markers of different candidate atherogenic risk parameters were also studied and the potential existence of a progressive relation between the number of metabolic syndrome components and the above mentioned biomarkers was analyzed. Thirty one male patients with metabolic syndrome (ATPIII definition) and 56 male control subjects were studied. We evaluated different markers of insulin resistance, inflammation and atherosclerosis, as well as protective factors. Patients with metabolic syndrome showed (a) hypoadiponectinemia (4551 +/- 2302 ng/ml vs. 5865 +/- 2548 ng/ml, respectively; p<0.05), (b) an atherogenic lipid and lipoprotein profile, (c) altered HDL chemical composition accompanied by higher cholesteryl ester-triglyceride interchange carried out by CETP, (d) diminished Lp-PLA(2) activity (6.5 +/- 1.9 vs. 7.3 +/- 2.2, p<0.05, respectively), antioxidant enzyme related with LDL oxidation, which was positively associated with QUICKI and negatively with VCAM-1 and lymphocyte CD18, and (e) high soluble (VCAM-1: 17 +/-5 vs. 13 +/- 4 ng/ml, respectively; p<0.0005) and leukocyte adhesion molecule expression (monocyte CD54: 52 +/- 15 vs. 45 +/-12 arbitrary units, respectively; p<0.0005; and lymphocyte CD49d: 312 +/- 56 vs. 284 +/- 64 arbitrary units, respectively; p < 0.05). The increment in leukocyte and soluble cell adhesion molecules, crucial for leukocyte interaction with the endothelium and migration into the artery wall, in combination with the other disorders described above reinforce the presence of a clinical status with high propensity to type 2 diabetes and atherosclerotic cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096167     DOI: 10.1016/j.atherosclerosis.2007.11.007

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

Review 2.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  High sensitivity C-reactive protein, tumor necrosis factor-α, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105).

Authors:  Karunakaran Indulekha; Jayagopi Surendar; Viswanathan Mohan
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

4.  Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?

Authors:  Yucel Arman; Adem Atici; Ozgur Altun; Remzi Sarikaya; Sengül Aydin Yoldemir; Murat Akarsu; Orkide Kutlu; Guzin Zeren Ozturk; Pinar Demir; Mustafa Ozcan; Recep Yilmaz Bayraktarli; Tufan Tukek
Journal:  Arq Bras Cardiol       Date:  2022-08-05       Impact factor: 2.667

Review 5.  Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome.

Authors:  Sridevi Devaraj; Simona Valleggi; David Siegel; Ishwarlal Jialal
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

6.  Age-related differences in integrin expression in peripheral blood lymphocytes.

Authors:  Christine V Crooks; Martin L Cross; Clare R Wall
Journal:  Immun Ageing       Date:  2010-04-26       Impact factor: 6.400

7.  Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system.

Authors:  Boglarka Laczy; Bradford G Hill; Kai Wang; Andrew J Paterson; C Roger White; Dongqi Xing; Yiu-Fai Chen; Victor Darley-Usmar; Suzanne Oparil; John C Chatham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-21       Impact factor: 4.733

8.  Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study.

Authors:  Florencia S Pierini; Eliana Botta; Enrique R Soriano; Maximiliano Martin; Laura Boero; Tomás Meroño; María Soledad Saez; Ezequiel Lozano Chiappe; Osvaldo Cerda; Gustavo Citera; Ignacio Gandino; Javier Rosa; Patricia Sorroche; Anatol Kontush; Fernando Brites
Journal:  Rheumatol Ther       Date:  2021-04-02

9.  Acute and long term effects of grape and pomegranate juice consumption on endothelial dysfunction in pediatric metabolic syndrome.

Authors:  Roya Kelishadi; Samuel S Gidding; Mohammad Hashemi; Mahin Hashemipour; Afshin Zakerameli; Parinaz Poursafa
Journal:  J Res Med Sci       Date:  2011-03       Impact factor: 1.852

10.  Impaired Circulating Angiogenic Cells Mobilization and Metalloproteinase-9 Activity after Dynamic Exercise in Early Metabolic Syndrome.

Authors:  Natalia G Rocha; Allan R K Sales; Leticia A Penedo; Felipe S Pereira; Mayra S Silva; Renan L Miranda; Jemima F R Silva; Bruno M Silva; Aline A Santos; Antonio C L Nobrega
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.